OpGen (NASDAQ:OPGN) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of OpGen (NASDAQ:OPGN) in a report released on Friday. The brokerage issued a sell rating on the medical research company’s stock.

OpGen Stock Down 5.0 %

OpGen stock opened at $1.90 on Friday. OpGen has a one year low of $1.75 and a one year high of $38.40. The business’s fifty day moving average is $2.50 and its 200 day moving average is $3.89.

OpGen (NASDAQ:OPGN) last released its quarterly earnings data on Monday, July 8th. The medical research company reported $0.21 EPS for the quarter. OpGen had a negative return on equity of 1,827.76% and a negative net margin of 1,140.36%. The company had revenue of $0.17 million for the quarter.

Institutional Investors Weigh In On OpGen

A hedge fund recently bought a new stake in OpGen stock. Chase Investment Counsel Corp bought a new position in OpGen, Inc. (NASDAQ:OPGN) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 331,890 shares of the medical research company’s stock, valued at approximately $230,000. Chase Investment Counsel Corp owned about 2.63% of OpGen as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 2.68% of the company’s stock.

About OpGen

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.